### Guidelines for Treatment of Malaria in the United States

*(Based on drugs currently available for use in the United States)*

**CDC Malaria Hotline:** (770) 488-7788 Monday-Friday 8 am to 4:30 pm EST  
(770) 488-7100 after hours, weekends and holidays (ask to page the malaria person on-call)

<table>
<thead>
<tr>
<th>Clinical Diagnosis/Plasmodium species</th>
<th>Region Infection Acquired</th>
<th>Recommended Drug and Adult Dose</th>
<th>Recommended Drug and Pediatric Dose</th>
</tr>
</thead>
</table>
| **Uncomplicated malaria/**  
**P. falciparum or Species not identified** | Chloroquine-sensitive  
(Central America west of Panama Canal; Haiti;  
The Dominican Republic; and most of the Middle East) | Chloroquine phosphate (Aralen™ and generics)  
600 mg base (=1,000 mg salt) po immediately, followed by  
300 mg base (=500 mg salt) po at 6, 24, and 48 hours  
Total dose: 1,500 mg base (=2,500 mg salt)  
2nd line alternative for treatment:  
Hydroxychloroquine (Plaquenil™ and generics)  
620 mg base (=800 mg salt) po immediately, followed by  
310 mg base (=400 mg salt) po at 6, 24, and 48 hours  
Total dose: 1,550 mg base (=2,000 mg salt) | Chloroquine phosphate (Aralen™ and generics)  
10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours  
Total dose: 25 mg base/kg  
2nd line alternative for treatment:  
Hydroxychloroquine (Plaquenil™ and generics)  
10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours  
Total dose: 25 mg base/kg |
| Chloroquine-resistant or unknown resistance†  
(All malarial regions except those specified as chloroquine-sensitive listed in the box above.  
Middle Eastern countries with chloroquine-resistant *P. falciparum* include Iran, Oman,  
Saudi Arabia, and Yemen. Of note, infections acquired in the Newly Independent States of the  
former Soviet Union and Korea to date have been uniformly caused by *P. vivax* and should  
therefore be treated as chloroquine-sensitive infections.) | A. Quinine sulfate⁷ plus one of the following:  
Doxycycline, Tetracycline, or Clindamycin  
Quinine sulfate: 542 mg base (=650 mg salt)⁴ po tid  
x 3 to 7 days  
Doxycycline: 100 mg po bid x 7 days  
Tetracycline: 250 mg po qid x 7 days  
Clindamycin: 20 mg base/kg/day po divided tid x 7 days  
B. Atovaquone-proguanil (Malarone™)⁴  
Adult tab = 250 mg atovaquone/100 mg proguanil  
4 adult tabs po qd x 3 days  
B. Atovaquone-proguanil (Malarone™)⁴  
Adult tab = 250 mg atovaquone/100 mg proguanil  
Peds tab = 62.5 mg atovaquone/25 mg proguanil  
5-8 kg: 2 peds tabs po qd x 3 d  
9-10 kg: 3 peds tabs po qd x 3 d  
11-20 kg: 1 adult tab po qd x 3 d  
21-30 kg: 2 adult tabs po qd x 3 d  
31-40 kg: 3 adult tabs po qd x 3 d  
> 40 kg: 4 adult tabs po qd x 3 d  
C. Mefloquine (Lariam™ and generics)⁴  
684 mg base (=750 mg salt) po as initial dose, followed by  
456 mg base (=500 mg salt) po given 6-12 hours after  
initial dose  
Total dose= 1,250 mg salt  
C. Mefloquine (Lariam™ and generics)⁴  
13.7 mg base/kg (=15 mg salt/kg) po as initial dose,  
followed by 9.1 mg base/kg (=10 mg salt/kg) po given  
6-12 hours after initial dose  
Total dose= 25 mg salt/kg | A. Quinine sulfate⁷ plus one of the following:  
Doxycycline⁴, Tetracycline⁴ or Clindamycin  
Quinine sulfate: 8.3 mg base/kg (=10 mg salt/kg)³ po tid  
x 3 to 7 days  
Doxycycline: 2.2 mg/kg po every 12 hours x 7 days  
Tetracycline: 25 mg/kg/day po divided qid x 7 days  
Clindamycin: 20 mg base/kg/day po divided tid x 7 days  
B. Atovaquone-proguanil (Malarone™)⁴  
Adult tab = 250 mg atovaquone/100 mg proguanil  
Peds tab = 62.5 mg atovaquone/25 mg proguanil  
5-8 kg: 2 peds tabs po qd x 3 d  
9-10 kg: 3 peds tabs po qd x 3 d  
11-20 kg: 1 adult tab po qd x 3 d  
21-30 kg: 2 adult tabs po qd x 3 d  
31-40 kg: 3 adult tabs po qd x 3 d  
> 40 kg: 4 adult tabs po qd x 3 d  
C. Mefloquine (Lariam™ and generics)⁴  
13.7 mg base/kg (=15 mg salt/kg) po as initial dose,  
followed by 9.1 mg base/kg (=10 mg salt/kg) po given  
6-12 hours after initial dose  
Total dose= 25 mg salt/kg |
| **Uncomplicated malaria/**  
**P. malariae** | All regions | Chloroquine phosphate: Treatment as above  
2nd line alternative for treatment:  
Hydroxychloroquine: Treatment as above | Chloroquine phosphate: Treatment as above  
2nd line alternative for treatment:  
Hydroxychloroquine: Treatment as above |

---

1. **NOTE:** There are three options (A, B, or C) available for treatment of uncomplicated malaria caused by chloroquine-resistant *P. falciparum*. Options A and B are equally recommended. Because of a higher rate of severe neuropsychiatric reactions seen at treatment doses, we do not recommend option C (mefloquine) unless options A and B cannot be used. For option A, because there is more data on the efficacy of quinine in combination with doxycycline or tetracycline, these treatment combinations are generally preferred to quinine in combination with clindamycin.

2. For infections acquired in Southeast Asia, quinine treatment should continue for 7 days. For infections acquired in Africa and South America, quinine treatment should continue for 3 days.

3. A US manufactured quinine sulfate capsule is in a 324mg dosage; therefore 2 capsules should be sufficient for adult dosing. Pediatric dosing should be sufficient due to unavailability of non-capsule forms of quinine. If unable to provide pediatric doses of quinine, consider malarone (recommendation B) or mefloquine (recommendation C).

4. Doxycycline and tetracycline are not indicated for use in children less than 8 years old. For children less than 8 years old with chloroquine-resistant *P. falciparum*, quinine (given alone for 7 days or given in combination with clindamycin) and atovaquone-proguanil are recommended treatment options; mefloquine can be considered if no other options are available. For children less than 8 years old with chloroquine-resistant *P. vivax*, quinine (given alone for 7 days) or mefloquine are recommended treatment options. If none of these treatment options are available or are not being tolerated and if the treatment benefits outweigh the risks, doxycycline or tetracycline may be given to children less than 8 years old.

5. Give atovaquone-proguanil with food. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose.

6. Treatment with mefloquine is not recommended in persons who have acquired infections from the Southeast Asian region of Burma, Thailand, and Cambodia due to resistant strains.

7. For infections in children with *P. falciparum* or *P. malariae*, treatment should not exceed adult dose.
### Guidelines for Treatment of Malaria in the United States

(Based on drugs currently available for use in the United States)

<table>
<thead>
<tr>
<th>Clinical Diagnosis/Region Infection Acquired</th>
<th>Recommended Drug and Adult Dose</th>
<th>Recommended Drug and Pediatric Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncomplicated malaria/Plasmodium species</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated malaria/All regions&lt;sup&gt;4&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Uncomplicated malaria/Chloroquine-resistant<sup>8</sup> Papua New Guinea and Indonesia | Chloroquine phosphate plus Primaquine phosphate<sup>7</sup>  
Chloroquine phosphate: Treatment as above  
Primaquine phosphate: 30 mg base po qd x 14 days  
2nd line alternative for treatment: Hydroxychloroquine plus Primaquine phosphate<sup>7</sup>  
Hydroxychloroquine: Treatment as above  
Primaquine phosphate: 30 mg base po qd x 14 days | Chloroquine phosphate plus Primaquine phosphate<sup>7</sup>  
Chloroquine phosphate: Treatment as above  
Primaquine phosphate: 0.5 mg base/kg po qd x 14 days  
2nd line alternative for treatment: Hydroxychloroquine plus Primaquine phosphate<sup>7</sup>  
Hydroxychloroquine: Treatment as above  
Primaquine phosphate: 30 mg base po qd x 14 days |
| Uncomplicated malaria/Chloroquine-sensitive<sup>12</sup> (see uncomplicated malaria sections above for chloroquine-sensitive Plasmodium species by region) | Chloroquine phosphate: Treatment as above  
2nd line alternative for treatment: Hydroxychloroquine: Treatment as above | Not applicable |
| Uncomplicated malaria: alternatives for pregnant women<sup>6,10,11,12</sup> |                                 |                                     |
| Chloroquine-resistant<sup>8</sup> (see uncomplicated malaria sections above for regions with known chloroquine-resistant Plasmodium falciparum) | Quinine sulfate<sup>7</sup> plus Clindamycin  
Quinine sulfate: Treatment as above  
Clindamycin: Treatment as above | Not applicable |
| Chloroquine-resistant<sup>8</sup> P. vivax<sup>9,10,11</sup> (see uncomplicated malaria sections above for regions with chloroquine-resistant P. vivax) | Quinine sulfate: 650 mg salt po tid x 7 days | Not applicable |

---

1. Primaquine is used to eradicate any hypnozoite forms that may remain dormant in the liver, and thus prevent relapses, in *P. vivax* and *P. ovale* infections. Because primaquine can cause hemolytic anemia in persons with G6PD deficiency, patients must be screened for G6PD deficiency prior to starting treatment with primaquine. For persons with borderline G6PD deficiency or as an alternate to the above regimen, primaquine may be given 45 mg orally one time per week for 8 weeks; consultation with an expert in infectious disease and/or tropical medicine is advised if this alternative regimen is considered in G6PD-deficient persons. Primaquine must not be used during pregnancy.

6. NOTE: There are two options (A or B) available for treatment of uncomplicated malaria caused by chloroquine-resistant *P. vivax*. High treatment failure rates due to chloroquine-resistant *P. vivax* have been well documented in Papua New Guinea and Indonesia. Rare case reports of chloroquine-resistant *P. vivax* have also been documented in Burma (Myanmar), India, and Central and South America. Persons acquiring *P. vivax* infections outside of Papua New Guinea or Indonesia should be started on chloroquine. If the patient does not respond, the treatment should be changed to a chloroquine-resistant *P. vivax* regimen and CDC should be notified (Malaria Hotline number listed in infections, options A and B are equally recommended.

8. For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant *P. falciparum* or chloroquine-resistant *P. vivax* infection, treatment with doxycycline or tetracycline is generally not indicated. However, doxycycline or tetracycline may be used in combination with quinine (as recommended for non-pregnant adults) if other treatment options are not available or are not being tolerated, and the benefit is judged to outweigh the potential risks.

9. For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant *P. falciparum* infection, atovaquone-proguanil may be used if other treatment options are not available or are not being tolerated, and the benefit is judged to outweigh the potential risks. There are no data on the efficacy of atovaquone-proguanil in the treatment of chloroquine-resistant *P. vivax* infections.

10. Because there are no adequate, well-controlled studies of atovaquone and/or proguanil hydrochloride in pregnant women, atovaquone-proguanil is generally not recommended for use in pregnant women. For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant *P. falciparum* infection, atovaquone-proguanil may be used if other treatment options are not available or are not being tolerated, and the potential benefit is judged to outweigh the potential risks.

11. For *P. vivax* and *P. ovale* infections, primaquine phosphate for radical treatment of hypnozoites should not be given during pregnancy. The chemoprophylactic dose of chloroquine phosphate is 300 mg base (=500 mg salt) orally once per week. After delivery, pregnant patients who do not have G6PD deficiency should be treated with primaquine.
## Guidelines for Treatment of Malaria in the United States
(Based on drugs currently available for use in the United States)

### CDC Malaria Hotline: (770) 488-7788 Monday-Friday 8 am to 4:30 pm EST
(770) 488-7100 after hours, weekends and holidays (ask to page the malaria person on-call)

<table>
<thead>
<tr>
<th>Severe Malaria</th>
<th>All Regions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quinidine gluconate</strong> plus one of the following:</td>
<td><strong>Doxycycline</strong>, <strong>Tetracycline</strong>, or <strong>Clindamycin</strong></td>
</tr>
<tr>
<td><strong>Quinidine gluconate</strong>: 6.25 mg base/kg (=10 mg salt/kg) loading dose IV over 1-2 hrs, then 0.0125 mg base/kg/min (=0.02 mg salt/kg/min) continuous infusion for at least 24 hours. An alternative regimen is 15 mg base/kg (=24 mg salt/kg) loading dose IV infused over 4 hours, followed by 7.5 mg base/kg (=12 mg salt/kg) infused over 4 hours every 8 hours, starting 8 hours after the loading dose (see package insert). Once parasite density &lt;1% and patient can take oral medication, complete treatment with oral quinine, dose as above. Quinidine/quinine course = 7 days in Southeast Asia; = 3 days in Africa or South America.</td>
<td><strong>Doxycycline</strong>: Treatment as above. If patient not able to take oral medication, give 100 mg IV every 12 hours and then switch to oral doxycycline (as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days.</td>
</tr>
<tr>
<td><strong>Tetracycline</strong>: Treatment as above</td>
<td><strong>Tetracycline</strong>: Treatment as above</td>
</tr>
<tr>
<td><strong>Clindamycin</strong>: Treatment as above. If patient not able to take oral medication, give 10 mg base/kg loading dose IV followed by 5 mg base/kg IV every 8 hours. Switch to oral clindamycin (oral dose as above) as soon as patient can take oral medication. For IV use, avoid rapid administration. Treatment course = 7 days.</td>
<td><strong>Clindamycin</strong>: Treatment as above</td>
</tr>
</tbody>
</table>

### Investigational new drug (contact CDC for information):
**Artesunate followed by one of the following:**
**Atovaquone-proguanil (Malarone™),**<sup>5</sup> **Clindamycin, or Mefloquine**

---

<sup>13</sup> Persons with a positive blood smear OR history of recent possible exposure and no other recognized pathology who have one or more of the following clinical criteria (impaired consciousness/coma, severe normocytic anemia, renal failure, pulmonary edema, acute respiratory distress syndrome, circulatory shock, disseminated intravascular coagulation, spontaneous bleeding, acidosis, hemoglobinuria, jaundice, repeated generalized convulsions, and/or parasitemia of > 5%) are considered to have manifestations of more severe disease. Severe malaria is practically always due to *P. falciparum*.

<sup>14</sup> Patients diagnosed with severe malaria should be treated aggressively with parenteral antimalarial therapy. Treatment with IV quinidine should be initiated as soon as possible after the diagnosis has been made. Patients with severe malaria should be given an intravenous loading dose of quinine unless they have received more than 40 mg/kg of quinine in the preceding 48 hours or if they have received mefloquine within the preceding 12 hours. Consultation with a cardiologist and a physician with experience treating malaria is advised when treating malaria patients with quinine. During administration of quinine, blood pressure monitoring (for hypotension) and cardiac monitoring (for widening of the QRS complex and/or lengthening of the QTc interval) should be monitored continuously and blood glucose (for hypoglycemia) should be monitored periodically. Cardiac complications, if severe, may warrant temporary discontinuation of the drug or slowing of the intravenous infusion.

<sup>15</sup> Consider exchange transfusion if the parasite density (i.e., parasitemia) is > 10% OR if the patient has altered mental status, non-volume overload pulmonary edema, or renal complications. The parasite density can be estimated by examining a monolayer of red blood cells (RBCs) on the thin smear under oil immersion magnification. The slide should be examined where the RBCs are more or less touching (approximately 400 RBCs per field). The parasite density can then be estimated from the percentage of infected RBCs and should be monitored every 12 hours. Exchange transfusion should be continued until the parasite density is <1% (usually requires 8-10 units). IV quinine administration should not be delayed for an exchange transfusion and can be given concurrently throughout the exchange transfusion.

<sup>16</sup> Pregnant women diagnosed with severe malaria should be treated aggressively with parenteral antimalarial therapy.